Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$94.35 USD
+0.59 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Zacks News
Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results
by Zacks Equity Research
Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
What's in Store for Abbott Laboratories (ABT) in Q4 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) fourth-quarter 2023 results are likely to reflect solid base business momentum.
Integer Holdings (ITGR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) research and product development activities.
Veeva Systems (VEEV) Offerings Adopted by SK Life Science
by Zacks Equity Research
Veeva Systems' (VEEV) Vault Validation Management is expected to aid SK Life Science to accelerate validation processes for increased inspection readiness.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Inari (NARI) Preliminary Q4 Revenues Ride on Procedure Demand
by Zacks Equity Research
Inari's (NARI) preliminary revenues reflect healthy procedure volume growth on the back of the rising adoption of existing and newly launched products in the United States and international markets.
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
by Zacks Equity Research
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.
Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Avanos (AVNS) Preliminary Q4 Revenues Dampened by Lower Sales
by Zacks Equity Research
Avanos' (AVNS) revenue growth in the fourth quarter is likely to have been dampened by lower HA pain relief injection product sales.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
by Zacks Equity Research
Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
Cencora (COR) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.
Microbot Medical (MBOT) Announces Positive GLP Study Results
by Zacks Equity Research
Microbot Medical's (MBOT) latest favorable study results are likely to support its IDE submission to the FDA to commence its human clinical study.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.
Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.
MMSI or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MMSI vs. WST: Which Stock Is the Better Value Option?